Pay in 4 interest-free payments of $6.16 Learn more
Ships within 48 hours · Estimated delivery Sep 8 - Sep 13
Zhang Y, Fu Y, Jiang T, Liu B, Sun H, Zhang Y, et al
10 Future directions While preclinical evidence strongly supports ASTs neuroprotective properties, translation into clinical application requires well-defined priorities
Comparative effectiveness of glucose-lowering drugs for type 2 diabetes: a systematic review and network meta-analysis
Another study showed GLP-1 agonist use to be associated with lower risks for several substance use disorders." To view or add a comment, sign in A team of researchers from The National Institutes of Health (NIH), Copenhagen University Hospital, and international collaborators has reported the first evidence from a randomised controlled clinical trial showing that a GLP-1 receptor agonist may help reduce heavy drinking in people living with both #obesity and #alcohol use disorder
The models are standard, the endpoints are measurable, and the reported direction of effect is reasonably consistent across groups
US$ 27.34
US$ 22.11
US$ 28.32
